At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,084 enrolled
Drug / intervention
Omega-3 fatty acid ethyl estersdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Omega-3 Fatty Acid Ethyl Esters (Lotriga) Granular Capsules Special Drug Use Surveillance (Long-term Use Survey)
In Brief
An observational study evaluating Omega-3 fatty acid ethyl esters for Hyperlipidemia. Completed, enrolled 3,084 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical practice
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemia
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2013
First PostedJun 2014
Primary CompletionMay 2017
TodayJul 2026
First PostedJun 2, 2014
Enrollment StartMay 29, 2013
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 12.1 years ago
Interventions
Omega-3 fatty acid ethyl estersdrug
Omega-3 fatty acid ethyl esters granular capsules